Search research articles
Contact Us
Filters
Showing results (121-130 of 124) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 124 results.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|
October 27, 2017
Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A
Wen Xiao, Ning Lou, Hailong Ruan, et al.
Urologic Oncology
|
September 17, 2016
miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma
Ning Lou, An-Ming Ruan, Bin Qiu, et al.
BMC Cancer
|
January 24, 2018
Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma
Guang-Hua Xu, Ning Lou, Hang-Chuan Shi, et al.
Cancer Immunology, Immunotherapy : CII
|
November 24, 2021
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
Qiaoyun Tan, Liyuan Dai, Yanrong Wang, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 124) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 124 results.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|
October 27, 2017
Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A
Wen Xiao, Ning Lou, Hailong Ruan, et al.
Urologic Oncology
|
September 17, 2016
miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma
Ning Lou, An-Ming Ruan, Bin Qiu, et al.
BMC Cancer
|
January 24, 2018
Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma
Guang-Hua Xu, Ning Lou, Hang-Chuan Shi, et al.
Cancer Immunology, Immunotherapy : CII
|
November 24, 2021
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy
Qiaoyun Tan, Liyuan Dai, Yanrong Wang, et al.
Page
of 13